BLOCK LISTING SIX MONTHLY RETURN

RNS Number : 7735R

Allergy Therapeutics PLC

01 July 2020

 

BLOCK LISTING SIX MONTHLY RETURN

Date: 1 July 2020

Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

Name of applicant:		ALLERGY THERAPEUTICS PLC
Name of scheme:		Allergy Therapeutics plc 2013 Long Term Incentive Plan
Period of return:	From:	11 July 2018	To:	1 July 2020
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:		10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017
Balance of unallotted securities under scheme(s) from previous return:		7,949,152
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		-
Less:   Number of securities issued/allotted under scheme(s) during period:		1,117,188
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		6,831,964

Name of contact:	Sara Goldsbrough
Telephone number of contact:	[phone]

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

James Stearns, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Other adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

END

 

 

BLRKKDBDABKDBOK